Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to regain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties

Related to the Company's Business, as contained in the Company's

Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Nichol Harber

Genta Investor Relations

908-286-3980

info@genta.com

Genta Incorporated

Selected Condensed Consolidated Financial Data

(In thousands, except per share data)

(Unaudited)

Three Months Ended Twelve Months Ended

December 31 December 31

2007 2006 2007 2006

Product sales - net $ 267 $ 117 $ 580 $ 708

Cost of goods sold
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... Jan. 2 Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... Officer, will present a corporate update at the 26th ... January 7,2008 at 11:30 am (Pacific Standard Time) at ... be webcast live and may be accessed by visiting,Amicus, ...
... Inc. (Nasdaq: ALTH ) today announced that ... pre-specified 65-patient,safety review of data from the Company,s ... patients with relapsed or refractory peripheral,T-cell lymphoma (PTCL), ... the,protocol. This interim assessment was based upon an ...
Cached Medicine Technology:Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 2Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:11/23/2014)... To show thanks to new and old ... white evening dresses for weddings. Customers who need ... iFitDress.com is a distinguished dress manufacturer, and it is among ... customers for a very long time. The CEO of this ... will be able to buy not only a beautiful dress, ...
(Date:11/23/2014)... Washington, DC (PRWEB) November 23, 2014 ... monthly Tech Report , which features the latest ... a technology expert and reporter for NewsWatch, conducted the ... cameras are unique and powerful options in the car ... is rising and it can be hard to find ...
(Date:11/23/2014)... Utah (PRWEB) November 23, 2014 ... insurance reimbursement for small businesses, announced their new ... The End of Employer-Provided Health Insurance. ... is the greatest financial risk facing most American ... U.S. employers, small and large, when it comes ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, ... attire in order to prepare for the wedding season. ... 70% off. , UWDress.com is a reliable company that ... especially the new items -- formal wedding guest attire. This ... market, including superstar and princess. As one of the leading ...
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... to Attend Conference, LAS VEGAS, Sept. 10 ... http://www.skinvisible.com ), the developers,of Invisicare(R), a proprietary ... announced that Mr. Terry Howlett,President & CEO, will ... & Co.,Investor Summit on September 18, 2007 at ...
... Montague and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker ... of Massachusetts has,granted final approval of a $52.5 ... actions against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... a protein best known as a common marker of inflammation ... The research, published by Cell Press in the September issue ... a potential target for cancer treatment. , CRP is a ... during the process of inflammation in response to the inflammatory ...
... eating fattening foods and not getting enough exercise are all ... disease more so if you have a family history. ... women dont change these habits as often as men, even ... reporting in the September issue of the American Heart ...
... Expansion of Services Now Ranges From Birth Through ... The Exceptional,Children,s Foundation (ECF) announced today that it ... one of California,s largest and most,unique nonprofit organizations ... disabilities. As a result of the,merger, ECF becomes ...
... Abbott (NYSE:,ABT) -- the global health care company ... Index and the Dow Jones Sustainability North America,Index ... Abbott,s,continued leadership in business, environmental and social performance. ... approach to business," said,Miles D. White, chairman and ...
Cached Medicine News:Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Human C-reactive protein regulates myeloma tumor cell growth and survival 2Health News:Women less likely than men to change habits that increase heart disease risk 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2
... Available As One Unit, Shaped Like A Fan, ... Of A Phaco Incision. The Gauges Start At ... Up To With 100-Micron Increments. The ... Information As To The Preoperative And Postoperative Incision ...
... Unique Reversible Speculums Designed To ... By Flipping The Speculums Over, Allowing ... Palpebral Fissures To The Widest Possible ... Providing Unobstructed Around-The-Clock Access To The ...
... A Micrometer Handle, Designed To Dial An ... Single Footplate Allows Maximum Visibility, With Titanium ... Blade Tracks Better In Tissue, And Can ... Making A Paracentesis., ,Reusable, Autoclaveable, Made In The ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: